Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare Inc filing: The Vanguard Group submitted Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 0 shares representing 0% of Alignment Healthcare common stock. The filing explains an internal realignment by The Vanguard Group effective January 12, 2026 that led certain subsidiaries to report ownership separately.
Alignment Healthcare, Inc. director and Chief Executive Officer John E. Kao reported an open-market sale of 118,000 shares of Common Stock at a weighted-average price of $17.4783 per share. The sale was effected indirectly through JEK Trust, dated February 8, 2021, for which he serves as trustee, under a Rule 10b5-1 trading plan adopted on November 21, 2025. Following the transaction, indirect holdings through the trust were 2,354,641 shares, and a separate holding entry shows 1,784,868 shares held directly.
ALHC reported Form 144 sales by or for John E. Kao under 10b5-1 plans. The excerpt lists multiple reported dispositions of Common stock, including sales of $1,133,514.66 across transactions on 12/29/2025 and repeated sales of $3,273,558.00 and similar amounts in early 2026. The filings show routine plan-based sales rather than corporate actions.
Alignment Healthcare COO Sebastian Burzacchi reported an open-market sale of 15,361 shares of common stock. The shares were sold at a weighted-average price of $17.84 per share, in multiple trades between $17.40 and $18.24. According to the disclosure, the sale was required to cover tax withholding obligations tied to the vesting of restricted stock units and is described as non-discretionary. After this transaction, Burzacchi directly holds 258,630 shares.
Alignment Healthcare, Inc. Chief Medical Officer Hyong Kim reported an open-market sale of 18,404 shares of common stock at a weighted-average price of $17.84 per share. According to the filing, these shares were sold solely to cover tax withholding obligations from vesting restricted stock units and did not represent a discretionary trade.
After this transaction, Kim directly holds 367,701 shares of Alignment Healthcare common stock. The shares were sold in multiple trades at prices ranging from $17.40 to $18.24 per share.
Alignment Healthcare, Inc. Chief Legal and Administrative Officer Christopher J. Joyce reported an open-market sale of 25,125 shares of common stock on March 18, 2026. The shares were sold solely to cover tax withholding obligations tied to vesting restricted stock units and were not a discretionary trade.
The weighted-average sale price was $17.84 per share, with individual trades ranging from $17.40 to $18.24. After this tax-related sale, Joyce directly holds 323,464 shares of Alignment Healthcare common stock.
Alignment Healthcare, Inc. President Dawn Christine Maroney reported a mandatory sale of 36,749 shares of common stock. The shares were sold in open-market transactions at a weighted-average price of $17.84 per share to cover tax withholding obligations from vesting restricted stock units, and are described as non-discretionary. Following these transactions, Maroney directly holds 1,058,813 shares of Alignment Healthcare common stock. Individual sales occurred at prices ranging from $17.40 to $18.24 per share.
Alignment Healthcare, Inc. Chief Executive Officer John E. Kao reported an open-market sale of 73,046 shares of common stock at a weighted-average price of $17.84 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from vesting of restricted stock units and did not represent a discretionary trade.
After the sale, Kao directly owned 1,784,868 common shares. He also had an additional 2,472,641 shares held indirectly through the JEK Trust dated February 8, 2021, for which he serves as trustee.
Alignment Healthcare, Inc. Chief Information Officer Robert L. Scavo reported an open-market sale of 11,285 shares of common stock. The shares were sold primarily to cover tax withholding obligations tied to the vesting of restricted stock units, so the transaction was not a discretionary trade. The weighted-average sale price was $17.84 per share, with individual trades ranging from $17.40 to $18.24. After this tax-related sale, Scavo holds 487,685 shares of Alignment Healthcare common stock directly.
Alignment Healthcare, Inc. Chief Human Resources Officer Andreas P. Wagner reported open-market sales of Alignment Healthcare common stock primarily to cover tax withholding from vesting restricted stock units. He sold 12,000 shares on March 18, 2026 at a weighted-average price of $17.84 per share and 11,602 shares on March 19, 2026 at a weighted-average price of $18.2207 per share.
The filing states these sales were required to satisfy tax obligations and "do not represent a discretionary trade" by Wagner, and were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 21, 2025. After these transactions, he directly holds 148,628 shares of Alignment Healthcare common stock.